Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time
- 20 October 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (30), 3800-3806
- https://doi.org/10.1200/jco.2012.44.6716
Abstract
Purpose Denosumab, an anti–RANK ligand monoclonal antibody, significantly increases bone metastasis–free survival (BMFS; hazard ratio [HR], 0.85; P = .028) and delays time to first bone metastasis ...Keywords
This publication has 20 references indexed in Scilit:
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialThe Lancet, 2012
- Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasisClinical & Experimental Metastasis, 2007
- Clinical Features of Metastatic Bone Disease and Risk of Skeletal MorbidityClinical Cancer Research, 2006
- Regulation of cancer cell migration and bone metastasis by RANKLNature, 2006
- Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate CancerJournal of Clinical Oncology, 2005
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerThe New England Journal of Medicine, 2004
- Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.2003
- Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.2003
- Osteoprotegerin inhibits prostate cancer–induced osteoclastogenesis and prevents prostate tumor growth in the boneJCI Insight, 2001
- Metastatic patterns of prostate cancer: An autopsy study of 1,589 patientsHuman Pathology, 2000